Archives of Craniofacial Surgery (대한두개안면성형외과학회지)

Korean Cleft Palate-Craniofacial Association (대한두개안면성형외과학회)
권호 표지
DOI QR코드

DOI QR Code

Current understanding of angiosarcoma: disease biology and evolving treatment

  • Woo Ju Kim (Department of Plastic and Reconstructive Surgery, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University School of Medicine) ;
  • Han Koo Kim (Department of Plastic and Reconstructive Surgery, Chung-Ang University Hospital, Chung-Ang University School of Medicine)
  • Received : 2023.08.28
  • Accepted : 2023.09.12
  • Published : 2023.10.20
Download PDF
⟨ Previous Next ⟩

Abstract

Angiosarcoma is a very rare soft tissue sarcoma that originates from endothelial cells and typically has a poor prognosis. It is most commonly found in elderly white men and can occur anywhere in the body, particularly in the head, neck, and scalp. Patients who have undergone previous radiation treatment or who have chronic lymphedema also face an elevated risk of this condition. Various genetic changes are suspected to contribute to the development of angiosarcoma, and these changes have been identified as potential targets for treatment. For localized disease, wide surgical resection is often the prudent course of action. A multidisciplinary approach, which may include surgery, radiotherapy, systemic chemotherapy, or immunotherapy, is typically the most effective way to achieve favorable outcomes. In this review, we discuss the general understanding of angiosarcoma and its management, with a particular focus on the current evolving treatments for the disease.

Keywords

References

  1. Antonescu C. Malignant vascular tumors: an update. Mod Pathol 2014;27 Suppl 1:S30-8.  https://doi.org/10.1038/modpathol.2013.176
  2. Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD, et al. Angiosarcoma: clinical and molecular insights. Ann Surg 2010;251:1098-106.  https://doi.org/10.1097/SLA.0b013e3181dbb75a
  3. Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma: a report of 67 patients and a review of the literature. Cancer 1996;77:2400-6.  https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z
  4. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol 2010;11:983-91.  https://doi.org/10.1016/S1470-2045(10)70023-1
  5. Sturm EC, Marasco IS, Katz SC. Multidisciplinary management of angiosarcoma: a review. J Surg Res 2021;257:213-20.  https://doi.org/10.1016/j.jss.2020.07.026
  6. Florou V, Wilky BA. Current management of angiosarcoma: recent advances and lessons from the past. Curr Treat Options Oncol 2021;22:61. 
  7. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the french federation of cancer centers sarcoma group. Cancer 2001;91:1914-26.  https://doi.org/10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3
  8. Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer 2008;113:616-27.  https://doi.org/10.1002/cncr.23571
  9. Albores-Saavedra J, Schwartz AM, Henson DE, Kostun L, Hart A, Angeles-Albores D, et al. Cutaneous angiosarcoma: analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007. Ann Diagn Pathol 2011;15:93-7.  https://doi.org/10.1016/j.anndiagpath.2010.07.012
  10. Brenn T, Fletcher CD. Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. Am J Surg Pathol 2005;29:983-96.  https://doi.org/10.1097/01.pas.0000156664.04955.83
  11. Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 2002;52:1231-7.  https://doi.org/10.1016/S0360-3016(01)02799-7
  12. Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007;18:2030-6.  https://doi.org/10.1093/annonc/mdm381
  13. Weiss SW, Goldblum JR. Enzinger and weiss's soft tissue tumors. 5th ed. Mosby; 2008. 
  14. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. Cancer 1948;1:64-81.  https://doi.org/10.1002/1097-0142(194805)1:1<64::AID-CNCR2820010105>3.0.CO;2-W
  15. Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer 2009;115:4055-63.  https://doi.org/10.1002/cncr.24462
  16. Manner J, Radlwimmer B, Hohenberger P, Mossinger K, Kuffer S, Sauer C, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 2010;176:34-9.  https://doi.org/10.2353/ajpath.2010.090637
  17. Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 2001;92:172-80.  https://doi.org/10.1002/1097-0142(20010701)92:1<172::AID-CNCR1306>3.0.CO;2-K
  18. West JG, Weitzel JN, Tao ML, Carpenter M, West JE, Fanning C. BRCA mutations and the risk of angiosarcoma after breast cancer treatment. Clin Breast Cancer 2008;8:533-7.  https://doi.org/10.3816/CBC.2008.n.066
  19. Chaudhary P, Bhadana U, Singh RA, Ahuja A. Primary hepatic angiosarcoma. Eur J Surg Oncol 2015;41:1137-43.  https://doi.org/10.1016/j.ejso.2015.04.022
  20. Bosetti C, La Vecchia C, Lipworth L, McLaughlin JK. Occupational exposure to vinyl chloride and cancer risk: a review of the epidemiologic literature. Eur J Cancer Prev 2003;12:427-30.  https://doi.org/10.1097/00008469-200310000-00012
  21. Karkouche R, Kerob D, Battistella M, Soufir N, Hadj-Rabia S, Bagot M, et al. Angiosarcoma in patients with xeroderma pigmentosum: less aggressive and not so rare? J Am Acad Dermatol 2013;69:e142-3.  https://doi.org/10.1016/j.jaad.2013.03.011
  22. Qureshi YA, Strauss DC, Thway K, Fisher C, Thomas JM. Angiosarcoma developing in a non-functioning arteriovenous fistula post-renal transplant. J Surg Oncol 2010;101:520-3.  https://doi.org/10.1002/jso.21516
  23. Shustef E, Kazlouskaya V, Prieto VG, Ivan D, Aung PP. Cutaneous angiosarcoma: a current update. J Clin Pathol 2017;70:917-25.  https://doi.org/10.1136/jclinpath-2017-204601
  24. Morgan MB, Swann M, Somach S, Eng W, Smoller B. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol 2004;50:867-74.  https://doi.org/10.1016/j.jaad.2003.10.671
  25. Ohsawa M, Naka N, Tomita Y, Kawamori D, Kanno H, Aozasa K. Use of immunohistochemical procedures in diagnosing angiosarcoma: evaluation of 98 cases. Cancer 1995;75:2867-74.  https://doi.org/10.1002/1097-0142(19950615)75:12<2867::AID-CNCR2820751212>3.0.CO;2-8
  26. Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet 2014;46:376-9.  https://doi.org/10.1038/ng.2921
  27. Murali R, Chandramohan R, Moller I, Scholz SL, Berger M, Huberman K, et al. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget 2015;6:36041-52.  https://doi.org/10.18632/oncotarget.5936
  28. Udager AM, Ishikawa MK, Lucas DR, McHugh JB, Patel RM. MYC immunohistochemistry in angiosarcoma and atypical vascular lesions: practical considerations based on a single institutional experience. Pathology 2016;48:697-704.  https://doi.org/10.1016/j.pathol.2016.08.007
  29. Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003;98:1716-26.  https://doi.org/10.1002/cncr.11667
  30. Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 2007;14:1953-67.  https://doi.org/10.1245/s10434-006-9335-y
  31. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005;11:241-7.  https://doi.org/10.1097/00130404-200505000-00011
  32. Naka N, Ohsawa M, Tomita Y, Kanno H, Uchida A, Aozasa K. Angiosarcoma in Japan: a review of 99 cases. Cancer 1995;75:989-96.  https://doi.org/10.1002/1097-0142(19950215)75:4<989::AID-CNCR2820750414>3.0.CO;2-K
  33. Lahat G, Dhuka AR, Lahat S, Smith KD, Pollock RE, Hunt KK, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol 2009;16:2502-9.  https://doi.org/10.1245/s10434-009-0569-3
  34. Mocellin S, Rossi CR, Brandes A, Nitti D. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev 2006;32:9-27.  https://doi.org/10.1016/j.ctrv.2005.10.003
  35. Grassia KL, Peterman CM, Iacobas I, Margolin JF, Bien E, Padhye B, et al. Clinical case series of pediatric hepatic angiosarcoma. Pediatr Blood Cancer 2017;64:e26627. 
  36. Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp. Head Neck 2011;33:661-7.  https://doi.org/10.1002/hed.21513
  37. Dettenborn T, Wermker K, Schulze HJ, Klein M, Schwipper V, Hallermann C. Prognostic features in angiosarcoma of the head and neck: a retrospective monocenter study. J Craniomaxillofac Surg 2014;42:1623-8.  https://doi.org/10.1016/j.jcms.2014.05.002
  38. Lindet C, Neuville A, Penel N, Lae M, Michels JJ, Trassard M, et al. Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact: a retrospective analysis from the french sarcoma group (GSF/GETO). Eur J Cancer 2013;49:369-76.  https://doi.org/10.1016/j.ejca.2012.08.016
  39. Cassidy RJ, Switchenko JM, Yushak ML, Madden N, Khan MK, Monson DK, et al. The importance of surgery in scalp angiosarcomas. Surg Oncol 2018;27:A3-8.  https://doi.org/10.1016/j.suronc.2018.07.010
  40. Sinnamon AJ, Neuwirth MG, McMillan MT, Ecker BL, Bartlett EK, Zhang PJ, et al. A prognostic model for resectable soft tissue and cutaneous angiosarcoma. J Surg Oncol 2016;114:557-63.  https://doi.org/10.1002/jso.24352
  41. Mullins B, Hackman T. Angiosarcoma of the head and neck. Int Arch Otorhinolaryngol 2015;19:191-5.  https://doi.org/10.1055/s-0035-1547520
  42. Deyrup AT, McKenney JK, Tighiouart M, Folpe AL, Weiss SW. Sporadic cutaneous angiosarcomas: a proposal for risk stratification based on 69 cases. Am J Surg Pathol 2008;32:72-7.  https://doi.org/10.1097/PAS.0b013e3180f633a3
  43. Vorburger SA, Xing Y, Hunt KK, Lakin GE, Benjamin RS, Feig BW, et al. Angiosarcoma of the breast. Cancer 2005;104:2682-8.  https://doi.org/10.1002/cncr.21531
  44. Choi JH, Ahn KC, Chang H, Minn KW, Jin US, Kim BJ. Surgical treatment and prognosis of angiosarcoma of the scalp: a retrospective analysis of 14 patients in a single institution. Biomed Res Int 2015;2015:321896. 
  45. Harati K, Lehnhardt M. The changing paradigm of resection margins in sarcoma resection. Innov Surg Sci 2017;2:165-70.  https://doi.org/10.1515/iss-2017-0043
  46. Patel SH, Hayden RE, Hinni ML, Wong WW, Foote RL, Milani S, et al. Angiosarcoma of the scalp and face: the Mayo Clinic experience. JAMA Otolaryngol Head Neck Surg 2015;141:335-40.  https://doi.org/10.1001/jamaoto.2014.3584
  47. Shin JY, Roh SG, Lee NH, Yang KM. Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: systematic review and meta-analysis. Head Neck 2017;39:380-6.  https://doi.org/10.1002/hed.24554
  48. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647-54.  https://doi.org/10.1016/S0140-6736(97)08165-8
  49. DeMartelaere SL, Roberts D, Burgess MA, Morrison WH, Pisters PW, Sturgis EM, et al. Neoadjuvant chemotherapy-specific and overall treatment outcomes in patients with cutaneous angiosarcoma of the face with periorbital involvement. Head Neck 2008;30:639-46.  https://doi.org/10.1002/hed.20757
  50. Heinhuis KM, IJzerman NS, van der Graaf WT, Kerst JM, Schrage Y, Beijnen JH, et al. Neoadjuvant systemic treatment of primary angiosarcoma. Cancers (Basel) 2020;12:2251. 
  51. Young RJ, Natukunda A, Litiere S, Woll PJ, Wardelmann E, van der Graaf WT. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven european organisation for research and treatment of cancer soft tissue and bone sarcoma group trials. Eur J Cancer 2014;50:3178-86.  https://doi.org/10.1016/j.ejca.2014.10.004
  52. D'Angelo SP, Munhoz RR, Kuk D, Landa J, Hartley EW, Bonafede M, et al. Outcomes of systemic therapy for patients with metastatic angiosarcoma. Oncology 2015;89:205-14.  https://doi.org/10.1159/000381917
  53. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol 2008;26:5269-74.  https://doi.org/10.1200/JCO.2008.17.3146
  54. Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008;44:2433-6.  https://doi.org/10.1016/j.ejca.2008.07.037
  55. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034-7.  https://doi.org/10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P
  56. Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the italian rare cancer network. Ann Oncol 2012;23:501-8.  https://doi.org/10.1093/annonc/mdr066
  57. Tian Z, Zhang F, Li P, Wang J, Yang J, Zhang P, et al. Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma. BMC Cancer 2020;20:698. 
  58. Fujisawa Y, Fujimura T, Matsushita S, Yamamoto Y, Uchi H, Otsuka A, et al. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study. Br J Dermatol 2020;183:831-9.  https://doi.org/10.1111/bjd.19042
  59. Ravi V, Wagner M, Chen TW, Loong HH, Mennel RG, Yen CC, et al. A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma. J Clin Oncolo 2020;38(15_suppl):11517. 
  60. Koontz BF, Miles EF, Rubio MA, Madden JF, Fisher SR, Scher RL, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 2008;30:262-6.  https://doi.org/10.1002/hed.20674
  61. Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013;24:257-63.  https://doi.org/10.1093/annonc/mds237
  62. Dickson MA, D'Adamo DR, Keohan ML, D'Angelo SP, Carvajal RD, Gounder MM, et al. Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma. Sarcoma 2015;2015:532478. 
  63. Kollar A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, et al. Pazopanib in advanced vascular sarcomas: an EORTC soft tissue and bone sarcoma group (STBSG) retrospective analysis. Acta Oncol 2017;56:88-92.  https://doi.org/10.1080/0284186X.2016.1234068
  64. von Mehren M, Litwin S, Ravi V, Schuetze S, Movva S, Agulnik M, et al. Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS). J Clin Oncol 2019;37(15_suppl):11039. 
  65. Ravi V, Sanford EM, Wang WL, Ross JS, Ramesh N, Futreal A, et al. Antitumor response of VEGFR2- and VEGFR3-amplified angiosarcoma to pazopanib. J Natl Compr Canc Netw 2016;14:499-502.  https://doi.org/10.6004/jnccn.2016.0058
  66. Mehta CR, Liu L, Theuer C. An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial). Ann Oncol 2019;30:103-8.  https://doi.org/10.1093/annonc/mdy464
  67. Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016;17:1732-42.  https://doi.org/10.1016/S1470-2045(16)30507-1
  68. Pasquier E, Andre N, Street J, Chougule A, Rekhi B, Ghosh J, et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine 2016;6:87-95.  https://doi.org/10.1016/j.ebiom.2016.02.026
  69. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353-65.  https://doi.org/10.1016/S1470-2045(20)30445-9
  70. Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, et al. The angiosarcoma project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med 2020;26:181-7.  https://doi.org/10.1038/s41591-019-0749-z
  71. Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer 2019;7:213. 
  72. Momen S, Fassihi H, Davies HR, Nikolaou C, Degasperi A, Stefanato CM, et al. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Cold Spring Harb Mol Case Stud 2019;5:a004408. 
  73. Hamacher R, Kampfe D, Reuter-Jessen K, Pottgen C, Podleska LE, Farzaliyev F, et al. Dramatic response of a PD-L1-positive advanced angiosarcoma of the scalp to pembrolizumab. JCO Precis Oncol 2018;2:1-7.  https://doi.org/10.1200/PO.17.00107
  74. Huis In 't Veld EA, Grunhagen DJ, Verhoef C, Smith HG, van Akkooi ACJ, Jones R, et al. Isolated limb perfusion for locally advanced angiosarcoma in extremities: a multi-centre study. Eur J Cancer 2017;85:114-21.  https://doi.org/10.1016/j.ejca.2017.07.023
  75. Park YS, Kim JH, Kim KW, Lee IS, Yoon HK, Ko GY, et al. Primary hepatic angiosarcoma: imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization. Clin Radiol 2009;64:779-85.  https://doi.org/10.1016/j.crad.2009.02.019
  76. Pierce DB, Johnson GE, Monroe E, Loggers ET, Jones RL, Pollack SM, et al. Safety and efficacy outcomes of embolization in hepatic sarcomas. AJR Am J Roentgenol 2018;210:175-82.  https://doi.org/10.2214/AJR.16.17573
  77. Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres: safety, efficacy, and survival. Radiology 2008;247:507-15. https://doi.org/10.1148/radiol.2472062029